I. COMMENCED TRADING IN JANUARY

Company (Symbol)#

Date Filed

Date Comm.

Shares/Units (M)

Price

Shares Out (M)

Lead, Other Underwriters

Gross (M)

Net (M)


INITIAL OFFERINGS

There were no initial public offerings conducted in January.

Total: $0M

Number of IPOs in January: 0

Average value of January IPOs: $0M

Number of IPOs for 2002: 0

Total raised in IPOs in 2002: $0M

Average value of IPOs in 2002: $0M

FOLLOW-ON OFFERINGS

Antigenics
Inc.
(AGEN)1

11/27

1/11

4S

$15

33

UBS Warburg LLC (co-lead); Robertson Stephens (co-lead)

$60

$56

Medicure
Inc.
(Canada; CDNX: MPH)2

11/14

1/31

15.38U

C$0.65

N/A

Research Capital Corp.;
Desjardins Securities Inc.

C$10 (US $6.3)

N/A

OVERALLOTMENT OPTIONS EXERCISED

Bruker
AXS Inc.
(BAXS)3

7/27

1/9

1.35S

$6.50

56

UBS Warburg LLC (co-lead); Thomas Weisel Partners (co-lead); CIBC World Markets Corp.; SG Cowen Securities Corp.; Robert W. Baird & Co.

$8.775

N/A

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

N/A = Not available, applicable or reported.

CDNX = Canadian Venture Exchange

1 Antigenics' underwriters have an overallotment option on 600,000 shares.

2 Medicure completed its C$10M offering in January.

3 Bruker's IPO was conducted in December. The overallotment option for 1.35M shares was exercised in January.

Total: $75.08M

Number of follow-on offerings in January: 2

Average value of January follow-ons: $37.54M

Number of follow-on offerings in 2002: 2

Total raised in follow-ons in 2002: $75.08M

Average value of follow-ons in 2002: $37.54M

II. FILED AND PENDING

Company (Symbol/ Proposed Symbol)#*

Date Filed

Shares/Units (M)

Price Range

Shares Out (M)

Lead, Other Underwriters

Value (M)


INITIAL OFFERINGS

Aderis Pharma-
ceuticals
Inc.
(ADPX)1

1/11

N/A

N/A

N/A

UBS Warburg LLC (co-lead); CIBC World Markets Corp. (co-lead) RBC Capital Markets

$100

AgraQuest Inc.
(AGRQ)2

8/3

3.5S

$11-13

12.8

Merrill Lynch & Co. (co-lead); Stephens Inc. (co-lead)

$42

APBiotech (APBI;
unit of Nycomed Amersham plc)3

10/3/00

18.2S

$15-17

208.6

Morgan Stanley Dean Witter (co-lead); Goldman, Sachs & Co. (co-lead); Chase H&Q; Salomon Smith Barney

$291.2

CombiMatrix
Corp.
(CLMX)4

11/22/00

N/A

N/A

N/A

Salomon Smith Barney (co-lead); JP Morgan & Co. (co-lead)

$100

Corcept Thera-
peutics Inc.

(CORT)5

12/21

4S

$14-16

23.9

U.S. Bancorp Piper Jaffray (co-lead); CIBC World Markets Corp. (co-lead); Thomas Weisel Partners LLC

$60

diaDexus Inc.
(DDXS)6

11/20/00

7S

$12-14

31.1

Lehman Brothers Inc.; CIBC World Markets Corp.; Robertson Stephens Inc.; Fidelity Capital Markets

$91

DOV Pharma-
ceutical
Inc.
(DOVP)7

1/29

N/A

N/A

N/A

Lehman Brothers Inc. (co-lead); CIBC World Markets Corp. (co-lead); Lazard Freres; Fidelity Capital Markets

$86.25

Innovative Drug
Delivery Systems
Inc.
(IDDS)8

1/2

N/A

N/A

N/A

Thomas Weisel Partners LLC; Wells Fargo Securities Inc.

$69

NeoGenesis Pharmaceuticals
Inc. (NGPI)9

11/19

6.2S

$12-14

26.8

JP Morgan & Co.; Bear, Stearns & Co. Inc.; SG Cowen Securities Corp.

$80.6

Protarga Inc.
(PRTG)10

12/12

N/A

N/A

N/A

UBS Warburg LLC (co-lead); U.S. Bancorp Piper Jaffray (co-lead)

$75

Ribapharm Inc.
(RIBA)11

5/15

20S

$13-15

N/A

UBS Warburg LLC (co-lead); CIBC World Markets Corp. (co-lead)

$280

ViaCell Inc.
(VIAC)12

1/30

N/A

N/A

N/A

UBS Warburg LLC; Banc of America Securities LLC; U.S. Bancorp Piper Jaffray Inc.

$115

ZymoGenetics
Inc.
(ZGEN)13

9/10

10S

$12-14

N/A

Lehman Brothers Inc. (co-lead); Merrill Lynch & Co. (co-lead); Bear, Stearns & Co. Inc.; Pacific Growth Equities Inc.

$130

FOLLOW-ON OFFERINGS

Amylin Pharma-
ceuticals Inc.
(AMLN)14

12/14

10S

$8.50

77.7

Goldman Sachs & Co. (co-lead); Lehman Brothers Inc. (co-lead)

$85

Aphton Corp.
(APHT)15

1/31

1.5S

N/A

N/A

UBS Warburg LLC; Morgan Keegan & Co. Inc.

N/A

Ariad Pharma-
ceuticals Inc.
(ARIA)16

1/9

3S

$5.28

35.2

N/A

$15.84

Array BioPharma
Inc.
(ARRY)17

1/23

4.2S

$12.55

27.8

Lehman Brothers Inc.; UBS Warburg; Legg Mason Wood Walker Inc.; Thomas Weisel Partners LLC

$52.71

BioTransplant
Inc.
(BTRN)18

12/11

5S

$8.10

21.1

N/A

$40.5

Celgene Corp.
(CELG)19

12/21

N/A

N/A

75.6

N/A

$500

Cell Pathways
Inc.
(CLPA)20

2/7/01

N/A

N/A

N/A

N/A

$25

Cepheid Inc.
(CPHD)21

12/21

N/A

N/A

26.56

N/A

$35

Cerus Corp.
(CERS)22

8/13

N/A

N/A

15.7

N/A

$300

CollaGenex
Pharmaceuticals
Inc.
(CGPI)23

10/26

0.965S

$8.01

N/A

N/A

$7.7

Cytogen Corp.
(CYTO)24

10/26/00

10S

$2.50

79.8

N/A

$25

Exelixis Inc.
(EXEL)25

7/30

N/A

N/A

49.2

N/A

$150

Genaissance
Pharmaceuticals
Inc.
(GNSC)26

10/18

N/A

N/A

22.8

N/A

$35

Genaera Corp.
(GENR)27

11/21

N/A

N/A

N/A

N/A

$50

Geron Corp.
(GERN)28

1/30

N/A

N/A

N/A

N/A

$150

InSite Vision
Inc.
(AMEX:ISV)29

2/2/01

N/A

N/A

N/A

Ladenburg Thalmann & Co. (placement agent)

$40

InterMune Inc.
(ITMN)30

12/21

N/A

N/A

N/A

N/A

$150

Matrix Pharma-
ceuticals Inc.
(MATX)31

5/25

N/A

N/A

26

N/A

$30

Microcide Pharma-
ceuticals Inc.
(MCDE)32

2/12/01

N/A

N/A

N/A

N/A

$35

Myriad Genetics
Inc.
(MYGN)33

11/9

N/A

N/A

N/A

N/A

$250

NeoTherapeutics
Inc.
(NEOT)34

1/3/01

N/A

N/A

21.9

N/A

$50

NPS Pharmaceu-
ticals Inc.
(NPSP)35

1/7

N/A

N/A

N/A

N/A

$250

SangStat Medical
Corp.
(SANG)36

12/28

4S

$20.68

24.96

Merrill Lynch & Co.; JP Morgan H&Q; Thomas Weisel Partners LLC; Wells Fargo Securities LLC

$82.72

SciClone Pharma-
ceuticals Inc.
(SCLN)37

11/6

N/A

N/A

N/A

N/A

$20

Targeted Genetics
Corp.
(TGEN)38

12/13

8.84S

$2.57

N/A

N/A

$22.72

Tularik Inc.
(TLRK)39

8/14

N/A

N/A

49.2

N/A

$250


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange; AMEX = American Stock Exchange.

* Stock symbols for companies seeking to complete IPOs are proposed.

N/A = Not available, applicable or reported.

1 Aderis, formerly Discovery Therapeutics Inc., filed for its IPO to raise $100M. Details were not disclosed.

2 AgraQuest amended its prospectus in January to offer 3.5M shares. The value, $42M, is based on the offering price of $12 per share, the midpoint of the expected price range.

3 APBiotech's IPO value, $291.2M, is based on the sale of 18.2M shares at $16 each, the midpoint of the expected price range.

4 CombiMatrix did not disclose any further details.

5 Corcept's offering is for 4.5M shares, 4M sold by the company and 500,000 sold by a selling stockholder. The value of Corcept's offering, $60M, is based on the sale of 4M shares at $15 each, the midpoint of the expected price range.

6 diaDexus' IPO value, $91M, is based on the sale of 7M shares at $13, the midpoint of the expected price range. The underwriters have an overallotment option for 1.05M shares.

7 DOV filed for an IPO, hoping to raise as much as 86.25M.

8 Innovative Drug Delivery filed for an IPO, hoping to raise as much as $69M.

9 NeoGenesis' offering's value, $80.6M, is based on the sale of 6.2M shares at $13 each, the midpoint of the expected price range. The underwriters have an overallotment option for 930,000 shares.

10 Protarga filed for its IPO with hopes of raising $75M. It did not disclose the number of shares to be offered or the expected price range.

11 Ribapharm's IPO originally was proposed in June 2000. The company amended its prospectus in January, raising the number of shares to be offered from 18M to 20M. The value of the offering, $280M, is based on the offering price of $14, the midpoint of the expected price range. The underwriters have an overallotment option for 2.7M shares.

12 ViaCell filed for a $115M IPO. No further details were disclosed.

13 ZymoGenetics' offering value, $130M, is based on the sale of 10M shares at $13 each, the midpoint of the expected price range. The underwriters also have an overallotment option for 1.5M shares. ZymoGenetics completed its $120M IPO on Feb. 1.

14 Amylin's underwriters have an overallotment option for 1.5M shares. The value is based on the sale of 10M shares at $8.50 each, the closing stock price on Jan. 25.

15 Aphton filed a registration statement to sell 1.5M shares of common stock from time to time.

16 Ariad filed a shelf registration to sell up to 3M shares. At the Jan. 8 closing stock price, that could raise $15.84M.

17 Array's underwriters have an option to purchase up to 630,000 additional shares for overallotments. The value, $59M, is based on the Jan. 22 closing stock price.

18 BioTransplant filed a shelf registration statement to sell up to 5M shares of its common stock. The value of the offering, $40.5M, is based on the Dec. 11 opening stock price of $8.10.

19 Celgene filed a universal shelf registration to offer and sell common stock, debt securities and convertible debt securities, up to a total value of $500M.

20 Cell Pathways filed a shelf registration for the sale of $25M in common stock.

21 Cepheid filed a shelf registration statement to offer and sell up to $35M of its common stock, preferred stock, debt securities and warrants.

22 Cerus filed to sell up to $300M of common stock and debt in a shelf offering.

23 The value of CollaGenex's proposed offering, $7.7M, is based on the Oct. 26 closing stock price of $8.01.

24 Cytogen filed to offer 10M shares at about $2.50 each in a shelf registration. It privately placed 3M shares in January.

25 Exelixis filed a shelf registration to sell up to $150M in common stock.

26 Genaissance filed a shelf registration to offer and sell common stock, preferred stock, debt or warrants, up to a value of $35M.

27 Genaera filed a universal shelf registration statement for the sale of up to $50M in common stock, preferred stock or warrants to purchase common stock or preferred stock.

28 Geron filed a prospectus for the sale of up to $150M in debt securities, common or preferred stock and warrants.

29 InSite filed a shelf registration in February 2001 to sell $40M in stock.

30 InterMune filed a shelf registration to offer and sell up to $150M in stock.

31 Matrix filed a shelf registration covering up to $30M in securities. Matrix announced in January that Chiron Corp. plans to acquire the company.

32 Microcide filed a shelf registration for the sale of up to $35M in securities. (Microcide is now Essential Therapeutics Inc., formed through its merger with The Althexis Co. Inc.)

33 Myriad filed a shelf registration statement for the sale of up to $250M of various types of securities.

34 NeoTherapeutics filed a shelf registration covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M. In May, the company raised $6M in a private placement. In August, the company privately placed 600,000 shares, raising $2.01M. In November, it placed 950,000 shares, raising $3.8M. In December, it placed 0.77M shares, raising $2.95M.

35 NPS filed a shelf registration statement to offer and sell up to $250M of common stock, preferred stock and debt securities.

36 SangStat filed a prospectus supplement providing for the issuance of 4M shares, plus an additional 600,000 shares to cover overallotments. The value is based on the Jan. 17 closing stock price of $20.68.

37 SciClone filed to sell up to $20M in common and preferred stock, debt securities and warrants from time to time through a shelf offering.

38 Targeted Genetics filed a shelf registration statement for the sale of up to about 8.84M shares of common stock. The value is based on the Jan. 22 closing stock price of $2.57.

39 Tularik filed to sell up to $250M in common stock and debt securities.